Talaris, previously known as Regenerex and based on research at University of Louisville, will use the funding to advance its cell therapy into later-stage clinical development.

Talaris Therapeutics, a US-based biotechnology spinout of University of Louisville, closed a $100m series A round on Thursday led by Blackstone Life Sciences, with participation from Longitude Capital and Qiming Venture Partners USA.
Founded in 2002 as Regenerex, Talaris Therapeutics is working on one-time cell therapies to eliminate the need for chronic immunosuppression for organ transplant recipients. The company’s lead asset, FCR001, is primarily aimed at living donor kidney transplant recipients.
Talaris will use the series A funding…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in